WuXi Biologics and Bayer enter into acquisition agreementChristian Fernsby ▼ | January 16, 2020
WuXi Biologics and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.
Acquisition WuXi Biologics
Topics: WuXi Biologics Bayer acquisition
The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions.
Financial details were not disclosed. ■